Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · Real-Time Price · USD
0.642
-0.023 (-3.48%)
Nov 21, 2024, 11:39 AM EST - Market open
Adaptimmune Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -44.52 | -113.87 | -165.46 | -158.09 | -130.09 | -137.17 | Upgrade
|
| Depreciation & Amortization | 11.26 | 9.84 | 6.08 | 6.57 | 7.59 | 8.01 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.94 | -1.99 | 2.53 | 5.28 | 3.84 | -0.19 | Upgrade
|
| Stock-Based Compensation | 12.3 | 11.77 | 18.24 | 20.63 | 10.41 | 11.05 | Upgrade
|
| Other Operating Activities | 2.46 | -21.68 | -1.62 | 1.71 | -1.39 | 1.06 | Upgrade
|
| Change in Accounts Receivable | 4.84 | -1.29 | -9.81 | -19.36 | 1.75 | -1.44 | Upgrade
|
| Change in Accounts Payable | -0.12 | -9.09 | 4.41 | 4.21 | 3.87 | 5.51 | Upgrade
|
| Change in Unearned Revenue | -37.65 | -14.57 | 3.87 | 149.79 | 47.97 | 2.1 | Upgrade
|
| Change in Other Net Operating Assets | 0.55 | - | - | - | 2.46 | -1.45 | Upgrade
|
| Operating Cash Flow | -53.68 | -140.88 | -141.77 | 10.73 | -53.59 | -112.51 | Upgrade
|
| Capital Expenditures | -1.49 | -4.68 | -29.5 | -8.57 | -2.34 | -1.59 | Upgrade
|
| Cash Acquisitions | - | 45.26 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.88 | -0.2 | -0.24 | -0.21 | -0.57 | -1.48 | Upgrade
|
| Investment in Securities | 3.11 | 135.03 | 118.88 | 84.58 | -276.02 | 98.02 | Upgrade
|
| Other Investing Activities | 0.34 | 1.12 | - | - | - | - | Upgrade
|
| Investing Cash Flow | 1.08 | 176.54 | 89.14 | 75.8 | -278.92 | 94.95 | Upgrade
|
| Net Debt Issued (Repaid) | 49.5 | - | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 29.32 | 0.88 | 12.87 | 3.29 | 340.05 | 0.37 | Upgrade
|
| Financing Cash Flow | 78.82 | 0.88 | 12.87 | 3.29 | 340.05 | 0.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.13 | 0.88 | -2.3 | 0.37 | -0.96 | -0.37 | Upgrade
|
| Net Cash Flow | 26.35 | 37.42 | -42.06 | 90.18 | 6.58 | -17.57 | Upgrade
|
| Free Cash Flow | -55.17 | -145.56 | -171.27 | 2.16 | -55.93 | -114.1 | Upgrade
|
| Free Cash Flow Margin | -31.52% | -241.47% | -630.86% | 35.05% | -1413.14% | -10169.25% | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.72 | -1.06 | 0.01 | -0.39 | -1.09 | Upgrade
|
| Cash Income Tax Paid | 4 | 4 | 0.63 | 0.54 | 0.08 | 0.2 | Upgrade
|
| Levered Free Cash Flow | -32.99 | -73.76 | -109.8 | -75.01 | -62.81 | -68.94 | Upgrade
|
| Unlevered Free Cash Flow | -31.97 | -73.76 | -109.8 | -75.01 | -62.81 | -68.94 | Upgrade
|
| Change in Net Working Capital | 11.27 | 4.22 | 3.34 | -7.98 | -5.46 | -2.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.